Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
Focus on SER-287 and SER-301, Seres’ microbiome therapeutic candidates in development for ulcerative colitis
Event to be held ahead of Phase 2b ECO-RESET study clinical induction results anticipated in mid-2021, with additional microbiome pharmacology data expected in H2 2021
During the event, Seres’ management and
Seres is conducting a Phase 2b trial of SER-287 in individuals with active mild-to-moderate UC. SER-287 is an oral microbiome therapeutic candidate designed to restructure the gastrointestinal microbiome and reduce inflammation. Topline clinical data from the SER-287 Phase 2b induction study are expected in mid-2021 and additional microbiome pharmacology data are expected in H2 2021. Seres is also evaluating SER-301, a cultivated rationally designed microbiome therapeutic candidate, in a Phase 1b study in individuals with active mild-to-moderate UC.
To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com. To access the event via conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 5387033.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the potential of microbiome therapeutics to treat and prevent disease, the timing and results of our clinical studies, the potential approval of any of our products, and other statements which are not historical fact.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; the impact of the COVID-19 pandemic; our unproven approach to therapeutic intervention; the lengthy, expensive and uncertain process of clinical drug development; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates and develop and commercialize our product candidates, if approved; and our ability to retain key personnel and to manage our growth. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005049/en/
PR Contact
kainsworth@serestherapeutics.com
IR Contact
ctanzi@serestherapeutics.com
Source: